Cytidine‐5'‐Diphosphocholine Protects the Liver From Ischemia/Reperfusion Injury Preserving Mitochondrial Function and Reducing Oxidative Stress

Cecilia Zazueta, Mabel Buelna‐Chontal, Arturo Macías‐López, Nadia G. Román‐Anguiano, Héctor González‐Pacheco, Natalia Pavón, Rashidi Springall, Alberto Aranda‐Frausto, Rafael Bojalil, Alejandro Silva‐Palacios, Rodrigo Velázquez‐Espejel, Sonia Galvan Arzate, Francisco Correa – 20 April 2018 – Cytidine‐5'‐diphosphocholine (CDP‐choline) participates as an intermediary in the synthesis of phosphatidylcholine, an essential component of cellular membranes.

LiverLearning®: 2018 Webinar: Cost-Effective Approach to Evaluation of Abnormal Liver Enzymes

This webinar will focus on best practices regarding evaluation of the patient presenting with abnormal liver enzymes. The focus will be not only on testing needed to arrive at the appropriate diagnosis, but also how to approach testing to minimize costs. This is an essential part of the daily practice for hepatologists and gastroenterologists.Vinay Sundaram (Moderator) Vinay Sundaram, MD, MSc is currently an Associate Professor of medicine and Director of Hepatology Outcomes Research at Cedars-Sinai Medical Center.

Fibroblast Growth Factor 15–Dependent and Bile Acid–Independent Promotion of Liver Regeneration in Mice

Bo Kong, Runbin Sun, Mingxing Huang, Monica D. Chow, Xiao‐Bo Zhong, Wen Xie, Yi‐Horng Lee, Grace L. Guo – 19 April 2018 – The role of intestine‐derived factors in promoting liver regeneration after partial hepatectomy (PHx) are not entirely known, but bile acids (BAs) and fibroblast growth factor 15 (Fgf15) that is highly expressed in the mouse ileum could promote hepatocyte proliferation. Fgf15 strongly suppresses the synthesis of BAs, and emerging evidence indicates that Fgf15 is important for liver regeneration.

Cirrhotic Cardiomyopathy After Transplantation: Neither the Transient Nor Innocent Bystander

Manhal Izzy, Jae Oh, Kymberly D. Watt – 19 April 2018 – Cirrhotic cardiomyopathy in end‐stage liver disease is currently characterized by blunted contractile systolic response to stress with or without diastolic dysfunction in the absence of known heart disease. Since the establishment of the diagnostic criteria of cirrhotic cardiomyopathy in 2005, there have been multiple studies regarding its pathophysiology and pretransplant clinical course. The data regarding the post‐transplant course of this entity are sparse.

Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus Infection

Nancy Reau, Paul Y. Kwo, Susan Rhee, Robert S. Brown, Kosh Agarwal, Peter Angus, Edward Gane, Jia‐Horng Kao, Parvez S. Mantry, David Mutimer, K. Rajender Reddy, Tram T. Tran, Yiran B. Hu, Abhishek Gulati, Preethi Krishnan, Emily O. Dumas, Ariel Porcalla, Nancy S. Shulman, Wei Liu, Suvajit Samanta, Roger Trinh, Xavier Forns – 19 April 2018 – Well‐tolerated, ribavirin‐free, pangenotypic hepatitis C virus (HCV) treatments for transplant recipients remain a high priority.

Subscribe to